Glioblastoma treated with postoperative radio-chemotherapy: Prognostic value of apparent diffusion coefficient at MR imaging

Yamasaki, Fumiyuki; Sakamoto, Kazuhiko; Ohtaki, Megu; Takeshima, Yukio; Abe, Nobukazu; Akiyama, Yuji; Takaba, Junko; Amatya, Vishwa Jeet; Saito, Taiichi; Kajiwara, Yoshinori; Hanaya, Ryosuke; Kurisu, Kaoru

doi:10.1016/j.ejrad.2009.01.013

Cited by 45 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reasons may be offered as explanations. First, the discrepancy between the present study and those results observed in primary CNS tumours [27][28][29] may also be owing to histopathological differences between different tissue types. Second, there can be biological differences between primary lesions and metastatic deposits [30].…”

Section: Discussioncontrasting

confidence: 54%

“…In fact, these histological features have been shown to adversely influence survival [22][23][24][25][26]. In malignant astrocytoma [27], glioblastoma [28] and primary central nervous system (CNS) lymphoma [29], a lower pre-treatment ADC has been shown to be associated with improved survival. However, the ability of ADC values in predicting survival in extracranial tumours and metastatic lesions has not yet been demonstrated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis

Tam¹,

Collins²,

Brown³

et al. 2013

BJR

View full text Add to dashboard Cite

Objective: To determine the prognostic value of pre-treatment apparent diffusion coefficient (ADC) of colorectal liver metastases in predicting disease response, progression-free survival (PFS) and overall survival (OS). Methods: We retrospectively reviewed 102 patients who underwent pre-treatment diffusion-weighted MRI using a breath-hold (b50, 150, 500) or a free-breathing (b50, 50, 100, 250, 500, 750) technique. The mean ADC (b50-500) and mean flow-insensitive ADC (ADC high ) values (breathhold: b5150 and 500; free-breathing: b5100 and 500) of up to three hepatic lesions were evaluated in each patient. Clinical and laboratory parameters were recorded. Tumour response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at 12 weeks after treatment. Associations between tumour response, ADC values and clinical/laboratory parameters were examined by one-way analysis of variance. The relationship of ADC with PFS and OS was determined by Kaplan-Meier analysis. Results: 62 patients responded to chemotherapy at 12 weeks. The pre-treatment mean ADC and mean ADC high were higher in the non-responding group than in the responding group (1.55 vs 1.36, p50.033; 1.40 vs 1.16, p50.024). However, the PFS and OS of the two groups of patients stratified by the median of mean ADC values or threshold derived by receiver operating characteristic analysis were not statistically significant. By multivariate Cox regression analysis, patients with #2 metastases and response to chemotherapy showed better PFS; white cell count #10 and surgical treatment were associated with better OS. Conclusion: Colorectal liver metastasis with higher pretreatment mean ADC and mean ADC high was associated with poorer response to chemotherapy. However, ADC and ADC high values did not predict the patient outcome in this study cohort. Advances in knowledge: High mean ADC values of colorectal liver metastases on pre-treatment diffusionweighted MRI is associated with poorer response to chemotherapy.Liver metastasis from colorectal cancer is common and is associated with poor survival. It has been shown that liver metastectomy [1], radiofrequency ablation [2] and good response to chemotherapy confer a favourable long-term outcome [3]. Given the impact of adverse effects of current treatments on quality of life, knowledge on the likelihood to respond to chemotherapy, progression-free survival (PFS) and overall survival (OS) will also facilitate clinical decision making on how aggressively to pursue the various therapeutic options.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionmentioning

confidence: 99%

The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis

Tam¹,

Collins²,

Brown³

et al. 2013

BJR

View full text Add to dashboard Cite

show abstract

“…Indeed, the ADC has been shown to correlate also with prognosis and treatment responses in patients with high-grade gliomas. In particular, a low pretreatment ADC value predicts a less favorable prognosis if compared with higher values [31,32].…”

Section: Discussionmentioning

confidence: 99%

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas

Feraco

Bacci

Ferrazza³

et al. 2020

Diagnostics

View full text Add to dashboard Cite

The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) can noninvasively predict the most common IDH mutational status (R132H) in GIII-astrocytomas and the overall survival (OS). Hence, twenty-two patients (9-F, 13-M) with a histological diagnosis of GIII-astrocytoma and evaluation of IDH-mutation status (12-wild type, 10-mutant) were retrospectively evaluated. Imaging studies were reviewed for the morphological feature and mean ADC values (ADCm). Statistics included a Fisher’s exact test, Student’s t-test, Spearman’s Test and receiver operating characteristic analysis. A p ≤ 0.05 value was considered statistically significant for all the tests. A younger age and a frontal location were more likely related to mutational status. IDH-wild type (Wt) exhibited a slight enhancement (p = 0.039). The ADCm values in IDH-mutant (Mut) patients were higher than those of IDH-Wt patients (p < 0.0004). The value of ADC ≥ 0.99 × 10−3 mm2/s emerged as a “cut-off” to differentiate the mutation state. In the overall group, a positive relationship between the ADCm values and OS was detected (p = 0.003; r = 0.62). Adding quantitative measures of ADC values to conventional MR imaging could be used routinely as a noninvasive marker of specific molecular patterns.

show abstract

“…Prior literature on the use of ADC in brain tumors reports the use of a single ADC threshold to distinguish high ADC, due to low cellularity vasogenic edema and necrosis from intermediate ADC, due to high cellularity tumor [30]. In addition to typical high ADC necrosis, an additional form of necrosis—sometimes referred to as “gelatinous necrosis”—has been described, characterized by very low ADC in the area of necrosis [19, 29].…”

Section: Discussionmentioning

confidence: 99%

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

Qin

Stroiney

et al. 2017

Neuroradiology

View full text Add to dashboard Cite

Introduction We describe the imaging findings encountered in GBM patients receiving immune checkpoint blockade and assess the potential of quantitative MRI biomarkers to differentiate patients who derive therapeutic benefit from those who do not. Methods A retrospective analysis was performed on longitudinal MRIs obtained on recurrent GBM patients enrolled on clinical trials. Among 10 patients with analyzable data, bidirectional diameters were measured on contrast enhanced T1 (pGd-T1WI) and volumes of interest (VOI) representing measurable abnormality suggestive of tumor were selected on pGdT1WI (pGdT1 VOI), FLAIR-T2WI (FLAIR VOI), and ADC maps. Intermediate ADC (IADC) VOI represented voxels within the FLAIR VOI having ADC in the range of highly cellular tumor (0.7–1.1 × 10−3 mm2/s) (IADC VOI). Therapeutic benefit was determined by tissue pathology and survival on trial. IADC VOI, pGdT1 VOI, FLAIR VOI, and RANO assessment results were correlated with patient benefit. Results Five patients were deemed to have received therapeutic benefit and the other five patients did not. The average time on trial for the benefit group was 194 days, as compared to 81 days for the no benefit group. IADC VOI correlated well with the presence or absence of clinical benefit in 10 patients. Furthermore, pGd VOI, FLAIR VOI, and RANO assessment correlated less well with response. Conclusion MRI reveals an initial increase in volumes of abnormal tissue with contrast enhancement, edema, and intermediate ADC suggesting hypercellularity within the first 0–6 months of immunotherapy. Subsequent stabilization and improvement in IADC VOI appear to better predict ultimate therapeutic benefit from these agents than conventional imaging.

show abstract

Glioblastoma treated with postoperative radio-chemotherapy: Prognostic value of apparent diffusion coefficient at MR imaging

Abstract: The ADC(MIN) value obtained from pretreatment MR images is a useful clinical prognostic biomarker in patients with glioblastoma.

Cited by 45 publications

References 20 publications

The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis

The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

Contact Info

Product

Resources

About